Neuromuskuläre Erkrankungen auf Intensivstation

Wolfgang Müllges †

doi:10.1055/a-1250-7249

Intensivmedizin up2date, Inhaltsverzeichnis

Intensivmedizin up2date 2021; 17(02): 247-266
DOI: 10.1055/a-1250-7249

Neuro-Intensivmedizin

Neuromuskuläre Erkrankungen auf Intensivstation

Wolfgang Müllges ^†

Abstract

Alle Artikel dieser Rubrik

Das Leitsymptom aller Krankheiten des peripheren Nervensystems, der neuromuskulären Synapsen und der Muskeln ist eine mehr oder weniger rasch progrediente Schwäche, die irgendwann zur Unfähigkeit zu gehen, zu schlucken, zu husten und schließlich zu atmen – und damit zur Intensivpflichtigkeit – führen kann. Dieser Artikel wendet sich an den allgemeinen Intensivmediziner und seine diagnostischen und therapeutischen Möglichkeiten.

Schlüsselwörter

Ateminsuffizienz - Polyneuropathie - myasthene Krise - akute Myopathie - Neuro-Intensivmedizin - Beatmung

Volltext

Referenzen

Literatur
1 Annane D, Quera Seva MA, Lofaso F. et al. Mechanisms underlying effects of nocturnal ventilation in daytime blood gases in neuromuscular disease. Eur Respir J 1999; 13: 157-162
2 Deutsche Gesellschaft für Pneumologie (federführend). Nichtinvasive und invasive Beatmung der chronischen respiratorischen Insuffizienz. AMWF S2k-Leitlinie 020–008. Im Internet (Stand: 14.04.2021): https://www.awmf.org/leitlinien/detail/ll/020-008.html
3 Müllges W, Stoll G. Intensivmedizinische Behandlung neuromuskulärer Krankheiten. Intensivmed up2date 2009; 5: 209-227
4 Thwaites CL. Tetanus. Pract Neurol 2002; 2: 130-137
5 Hughes RAC, Cornblath DR. Guillain-Barre-syndrome. Lancet 2005; 366: 1653-1666
6 Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007; 35: 691-711
7 Wijdicks EFM, Klein CJ. Guillain-Barré syndrome. Mayo Clin Proc 2017; 92: 467-479
8 Leonhard SE, Mandarakas MR, Gondim FAA. et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019; 15: 671-683
9 Mori K, Hattori N, Sugiura M. et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002; 58: 979-982
10 Kalita J, Ranjan A, Misra UK. Outcome of Guillain-Barre syndrome patients with respiratory paralysis. QJM 2016; 109: 319-323
11 Gold R, Dalakas MC, Toyka KV. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2003; 2: 22-32
12 Chevret S, Hughes AC, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2017; (02) CD001798
13 Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC. Intravenous immune globulins in patients with GBS: 3 days vs. 6 days. J Neurol Neurosurg Psychiatr 2001; 71: 235-238
14 Von Koningsveld R, Schmitz PIM, van der Meche FGA. et al. Effect on methylprednisolone when added to standard treatment with IVIG for GBS. Lancet 2004; 363: 192-196
15 Plasma Exchange/Sandoglobulin GBS Trial group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in GBS. Lancet 1997; 349: 225-230
16 Doets AY, Hughes RAC, Brassington R. et al. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2020; (01) CD008630
17 Müllges W, Stoll G. Akuttherapie des Guillain-Barré-Syndroms und der myasthenen Krise. Akt Neurol 2010; 37: 474-484
18 Zisimopoulou P, Brenner T, Trakas N. et al. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013; 12: 924-930
19 Müllges W, Stoll G. Myasthenia gravis. Nervenarzt 2019; 90: 1055-1066
20 Howard jr. JF. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 2018; 1412: 113-128
21 Roper J, Fleming ME, Long B. et al. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med 2017; 53: 843-853
22 Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol 2020; 11: 596981
23 Maselli RA, Ellis W, Mandler RN. Cluster of wound botulism in california: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997; 20: 1284-1295
24 Chalk CH, Benstead TJ, Pound JD. et al. Medical treatment for botulism. Cochrane Database Syst Rev 2019; (04) CD008123
25 Kohler S, Meisel A. Das Lambert-Eaton-Myasthenie Syndrom. Akt Neurol 2018; 45: 298-304
26 Barth D, Nabavi NM, Newe P. et al. Comparison of IVI g and PLEX in patients with myasthenia gravis. Neurology 2011; 76: 2017-2023
27 Liu JF, Wang WX, Xue J. et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 2010; 14: 153-160
28 Palace J, Newsom-Davis. Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50: 1778-1783
29 Sanders DB, Wolfe GI, Narayanaswami P. Developing treatment guidelines for myasthenia gravis. Ann N Y Acad Sci 2018; 1412: 95-101
30 Muppidi S, Utsugisawa K, Benatar M. et al. Long-term safety and efficiacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019; 60: 14-24
31 Meisel A, Schalke B, Henze T. et al. Stellungnahme zur Therapie mit Eculizumab im Erwachsenenalter. 2018. Im Internet (Stand: 14.04.2021): http://
32 Ferrero S, Pretta S, Nicoletti A. et al. Myasthenia gravis: management issues in pregnancy. Eur J Obst Gynecol Reproduct Biol 2005; 121: 129-138
33 Waters J. Management of myasthenia gravis in pregnancy. Neurol Clin 2019; 37: 113-120
34 Wolfe GI, Kaminski HJ, Aban IB. et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomized trial. Lancet Neurol 2019; 18: 259-268
35 Gamez J, Salvado M, Carmona F. et al. IVIG to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis. Ther Adv Neurol Disord 2019; 12: 1756286419864497
36 Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis. Yale J Biol Med 2013; 86: 255-260
37 Birnkrant DJ, Pope JF, Eiben RM. Management of the cardiorespiratory complications of neuromuscular disease in the pediatric intensive care unit. J Child Neurol 1999; 14: 139-143
38 Schneider-Gold C, Grimm T, Kress W. et al. Myotone Dystrophien. Akt Neurol 2010; 37: 348-359
39 Radelfahr F, Klopstock T. Mitochondriale Erkrankungen. Nervenarzt 2019; 90: 121-130
40 Müllges W, Naumann M, Reichmann H. Wird die chronische Dermato- oder Polymyositis als „Altersschwäche“ verkannt?. Dtsch Med Wochenschr 1993; 118: 1520-1524
41 Criddle LM. Rhabdomyolysis. Crit Care Nurs 2003; 23: 14-30
42 Gonzalez NL, Hobson-Webb LD. Neuromuscular ultrasound in clinical practice. Clin Neurophysiol Pract 2019; 4: 148-163
43 Paoletti M, Pichiecchio A, Piccinelli SC. et al. Advances in quantitative imaging of genetic and aquired myopathies. Front Neurol 2019; 10: 78
44 Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis – challenges in diagnosis and management. J Transl Autoimmun 2019; 2: 100018
45 Statland JM, Fontaine B, Hanna MG. et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve 2018; 57: 522-530
46 Girard T, Bandschapp O. Maligne Hyperthermie. Anästh Intensivmed 2019; 60: 135-143
47 Klingler W, Pfenninger E. Inhalative Analgosedierung auf der Intensivstation: Gefahr einer malignen Hyperthermie. Med Klin Intensivmed Notfmed 2020; 115: 101-106
48 Klingler W, Roewer N, Schuster F. et al. S1-Leitlinie: Therapie der malignen Hyperthermie. Anästh Intensivmed 2018; 59: 204-208
49 Tse L, Barr AM, Scarapicchia V. et al. Neuroleptic malignant syndrome: a review. Curr Neuropharmacol 2015; 13: 395-406
50 Van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of Neuroleptic Malignant syndrome. Psychopharmacol Bull 2019; 49: 84-91
51 Jacobs JM, Marcus EL, Stessman J. Prolonged mechanical ventilation: symptomatology, well-being, and attitudes to life. J Am Med Dir Assoc 2020;
52 Erbguth F. Ethische und juristische Aspekte der intensivmedizinischen Behandlung bei chronisch-progredienten neuromuskulären Erkrankungen. Intensivmedizin 2003; 40: 646-657
53 Oliver DJ, Borasio GD, Caraceni A. et al. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 2016; 23: 30-38
54 Danel-Brunaud V, Touzet L, Chevalier L. et al. Ethical considerations and palliative care in patients with amyotrophic lateral sclerosis: a review. Rev Neurol (Paris) 2017; 173: 300-307
55 Winzelberg GS, Hanson LC, Tulsky JA. Beyond autonomy: diversifying end-of-life decision-making approaches to serve patients and family. J Am Geriatr Soc 2005; 53: 1046-1050
56 Friedrich O, Reid MB, van den Berghe G. et al. The sick and the weak: neuropathies/myopathies in the critically ill. Physiol Rev 2015; 95: 1025-1109
57 Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med 2020; 6: 637-653
58 De Letter MA, Schmitz PI, Visser LH. et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29: 2281-2286
59 Müllges W, Stoll G. Critical-illness-Polyneuropathie und -Myopathie. Dtsch Med Wochenschr 2011; 136: 769-774
60 Pati S, Goodfellow JA, Iyadurai S. et al. Approach to critical illness polyneuropathy and myopathy. Postgrad J Med 2008; 84: 354-360
61 MacDuff A, Grant I S. Critical care management of neuromuscular disease, including long-term ventilation. Curr Opin Crit Care 2003; 9: 106-112
62 Müllges W. Nichtinvasive Beatmung bei neurologischen Intensivpatienten. Intensivmed Notfallmed 2001; 38: 54-58
63 Luo F, Annane D, Orlikowski D. et al. Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders. Cochrane Database Syst Rev 2017; (12) CD008380
64 Hutchinson D, Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol 2008; 8: 229-237
65 Grassi A, Ferlicca D, Lupieri E. et al. Assisted mechanical ventilation promotes recovery of diaphragmatic thickness in critically ill patients: a prospective observational study. Crit Care 2020; 24: 85
66 Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (federführend). Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz. AWMF S2k-Leitlinie 001–021. Im Internet (Stand: 14.04.2021): https://www.awmf.org/leitlinien/detail/ll/001-021.html
67 Walgaard C, Lingsma HF, van Doorn PA. et al. Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain-Barre syndrome. Neurocrit Care 2017; 26: 6-13
68 Weiss H, Rastan V, Müllges W. et al. Psychotic symptoms and emotional distress in patients with Guillain-Barré syndrome. Eur Neurol 2002; 47: 74-78
69 Ely EW, Inouye SK, Bernard GR. et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA 2001; 286: 2703-2710
70 Müllges W, Stoll G. Intensivmedizinische Behandlung neuromuskulärer Krankheiten. Intensivmed up2date 2009; 5: 209-227
71 Jonkman AH, Rauseo M, Carteaux G. et al. Proportional modes of ventilation: technology to assist physiology. Intensive Care Med 2020; 46: 2301-2313
72 Ciorba C, Gonzalez J, Quera-Salva MA. et al. Flow and airway pressure analysis for detecting ineffective effort during mechanical ventilation in neuromuscular patients. Chron Respir Dis 2019; 16: 1479972318790267
73 Neto S, Torres R, Lima I. et al. Weaning from mechanical ventilation in people with neuromuscular disease: protocol for a systematic review. BMJ Open 2019; 9: e029890
74 Morrow B, Argent A, Zampoli M. et al. Cough augmentation techniques for people with chronic neuromuscular disorders. Cochrane Database Syst Rev 2018; (11) CD013170
75 Annane D, Chevrolet J C, Chevret S. et al. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev 2000; (02) CD001941
76 Orlikowski D, Chevret S, Quera-Salva MA. et al. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults. Clin Ther 2009; 31: 1765-1773